<DOC>
	<DOC>NCT02462720</DOC>
	<brief_summary>The purpose of this study is to evaluate pain the patient experienced following treatment of varicose veins with Varithena® compared to radiofrequency ablation.</brief_summary>
	<brief_title>COMFORT: A Multicenter, Open-label, Randomized, Crossover Study</brief_title>
	<detailed_description>A study that evaluates pain following treatment of varicose veins in patients treated with Varithena® and those treated with RFA.</detailed_description>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Polidocanol</mesh_term>
	<criteria>1. Men and women; age 18 to 75 years 2. Bilateral incompetence of SFJ (reflux &gt;1 second on duplex ultrasonography) associated with incompetence of the GSV in both legs 3. GSV diameter &gt;5 mm measured from the superficial epigastric vein to 10 cm below the SFJ while in a standing position in both legs 4. Eligible to receive RFA treatment and Varithena® treatment 5. CEAP C2C5 (inclusive) 6. Patient is participating in usual work and home activities with no changes anticipated for the duration of the study 7. Ability to comprehend and sign an informed consent and complete study questionnaires written in English 8. Ability to reliably use an electronic diary to record pain and analgesic/opioid use in accordance with the protocol 1. Prior GSV treatment in either leg 2. Nonvenous source of pain in either leg that could confound the results of the study 3. Use of chronic analgesic or opiate medications or medical history that could result in the regular use of pain medications during the study 4. History of deep vein thrombosis, pulmonary embolism or stroke, including evidence of prior or active DVT on duplex ultrasound 5. Deep venous reflux unless clinically insignificant in comparison to superficial reflux 6. Inability to wear postprocedure compression bandaging and stockings 7. Reduced mobility (unable to walk unaided for 5 minutes per waking hour) 8. Major surgery, prolonged hospitalization or pregnancy within 3 months of screening 9. Major coexisting disease (e.g., malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.) 10. Contraindications to Varithena® (e.g., acute thromboembolic disease) or RFA according to the manufacturer's prescribing information 1. Varithena® contraindication due to known allergy to polidocanol 2. RFA contraindication due to veins being too large 3. RFA Contraindication due to veins being too tortuous 11. Known allergic response to polidocanol and/or multiple allergic reactions 12. Current or history of alcohol or drug abuse 13. Pregnant or lactating women 14. Women of childbearing potential not using effective contraception for at least one month prior to study treatment and/or unwilling to continue birth control for the duration of the study 15. Participation in a clinical study involving an investigational pharmaceutical product or device within the 3 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>